Lateral Flow Assay Development Services
Lateral Flow Assay Development Services
Assay Optimization
Refine assay conditions, performance parameters, and test architecture with intended use in mind — not just early bench success.
Reagent & Matrix Strategy
Assess how antibodies, antigens, conjugates, and sample conditions behave in the target matrix and expected use environment.
Verification Planning
Define the testing strategy and documentation needed to support performance claims and downstream development decisions.
Technology Transfer Support
Build development outputs that actually transfer. By treating handoff planning as a development requirement rather than a post-development task, programs arrive at transfer with fewer gaps to close.
Manufacturing Readiness
Prepare the assay for a more reliable transition into manufacturing by identifying key scale-up variables early — instead of discovering them after the bulk of development work is already complete.
Palladium supports biotech and IVD startups, diagnostic and OEM programs, and NGOs or decentralized testing initiatives that need a CDMO partner for lateral flow assay development, technology transfer, and manufacturing readiness.
Evaluating a new assay concept or trying to de-risk an existing program?
Build with Feasibility, Transfer, and Manufacturing in View
Most projects begin with some combination of the following. If some of these inputs are still being defined, a feasibility discussion can help clarify the right next step.
For a deeper overview of what the full lateral flow assay development process involves, see our process guide.
Moving into optimization before feasibility is established
Reagents and matrix conditions evaluated too late
Technology transfer planning deferred until late in development
Scale-up variables discovered after development is complete
Documentation gaps that slow decision-making and transfer
Start with a Feasibility Discussion
Most projects begin with some combination of the following. If some of these inputs are still being defined, a feasibility discussion can help clarify the right next step.
For a deeper overview of what the full lateral flow assay development process involves, see our process guide.
- A defined target analyte
- An intended use setting
- A target matrix
- Performance goals
- Existing antibodies, antigens, or preliminary technical data (if available)
What to Expect from a Feasibility Consultation
A feasibility consultation is designed to help your team make a better next decision. We use it to review your concept, identify key technical risks, and determine the most appropriate next phase for the program.
- Your assay concept and intended use
- What is already known and what still needs to be validated
- Matrix and reagent considerations
- Likely development risks and key assumptions to test first
- What an appropriate next-phase scope may look like
Frequently Asked Questions
What are lateral flow assay development services?
Lateral flow assay development services help teams move from an assay concept toward a functional, manufacturable rapid test through feasibility work, optimization, transfer planning, and manufacturing readiness support.
When should we engage a CDMO lateral flow partner?
The best time is often before major optimization work begins — especially if target matrix behavior, reagent selection, intended use, or scale-up path are still uncertain. Early engagement reduces the cost of decisions made on incomplete assumptions.
Do we need everything defined before contacting Palladium?
No. Many teams begin with a target, an intended use concept, and some early technical inputs. A feasibility discussion can help define the right path when parts of the program are still taking shape.
Can Palladium support technology transfer and manufacturing readiness?
Yes. Palladium’s development approach is built with technology transfer and manufacturing readiness in mind — to help reduce downstream handoff risk rather than address it as an afterthought.
Why does matrix matter so much in lateral flow development?
Because performance in buffer does not always translate to whole blood, saliva, urine, swab extracts, or other real sample types. Matrix conditions can significantly affect assay behavior and feasibility.
Is this service relevant for decentralized or field-use diagnostics?
Yes. Programs intended for point-of-care, decentralized, or field-use settings often require additional attention to robustness, usability, and environmental tolerance — factors that need to be considered early in development
We Know Where Lateral Flow Programs Go Wrong — and How to Help You Avoid It
If you’re evaluating a new assay concept, trying to de-risk an existing program, or looking for a CDMO partner that builds toward transfer and manufacturing from the start, schedule a feasibility consultation to identify the highest-priority risks and define the right next step.